SweetSpot of antidystonic effect in pallidal neurostimulation: a European multicentre imaging study
Objective: We investigated Volumes of Tissue activated (VTA) in dystonia subjects under DBS. We aimed to disentangle the SweetSpot for dystonia suppression within the pallidal region.…Safety and tolerability of deep brain stimulation in early stage Parkinson’s disease: Five-year follow-up of medication use and adverse events
Objective: To evaluate the long-term safety and tolerability of subthalamic nucleus deep brain stimulation (DBS) for early stage Parkinson’s disease (PD). Background: Twenty-nine subjects with…Deep Brain Stimulation for Parkinson’s disease: Short-term outcomes, referral patterns and health disparities.
Objective: To describe the practice patterns at University of Miami (UM), short term outcomes and health disparities among ethnic groups. Background: Deep brain stimulation (DBS)…UPDRS benefit from dual frequency DBS fields sculpted by intentionally overlapped interleaving
Objective: We show that UPDRS-III scores after interleaving compared to those prior to interleaving reflect a gain in benefit by lowered scores. Background: Previously, we…Factors determining the motor outcome of STN DBS in PD patients: Evidence for Dual Actions
Objective: We investigated factors determining the motor outcome of STN DBS in patients with Parkinson disease (PD). Background: The STN DBS has revolutionized the management…Baseline characteristics associated with greatest improvement in HRQL after DBS surgery
Objective: To determine the characteristics of DBS candidates associated with the greatest improvement in HRQL outcomes after surgery. Background: Site reviews of expert DBS centers…Off-Target Implications of Nurr1 Agonist Therapy in Parkinson’s disease
Objective: To examine the impact of Nurr1 agonists on regulation of striatal Nurr1 and levodopa (LD)-induced dyskinesias (LIDs) in a rat model of Parkinson’s disease…Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD): Efficacy, Safety, and Tolerability of Fixed-Dose Deutetrabenazine for the Treatment of Tardive Dyskinesia
Objective: To evaluate the efficacy, safety, and tolerability of deutetrabenazine in patients with tardive dyskinesia (TD). Background: AIM-TD is the second large 12-week, Phase III,…Improving Nursing Education on the care of those with Parkinson’s disease
Objective: The Edmond J. Safra Visiting Nurse Faculty Program at the Parkinson's DIsease Foundation provides a 40 contact hour accredited course for nursing faculty by linking…Ataxia and increased cerebrospinal fluid phosphate associated with a mutation in the SLC20A2 gene
Objective: To characterize the phenotype and biochemical abnormalities associated with the R467X mutation in the SLCA20A2 gene. Background: Mutations in the SLC20A2 gene are the…
- « Previous Page
- 1
- …
- 30
- 31
- 32
- 33
- 34
- …
- 155
- Next Page »